These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15842657)

  • 1. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
    Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH
    Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes.
    Banat GA; Usluoglu N; Hoeck M; Ihlow K; Hoppmann S; Pralle H
    Br J Haematol; 2004 Aug; 126(4):593-601. PubMed ID: 15287954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
    van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
    Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulating capacity of blast cells from patients with chronic myelocytic leukaemia, in blastic crisis in 'one-way' mixed lymphoycte reaction: lack of evidence for T lymphoblastic conversion.
    Han T; Gomez GA; Minowada J
    Immunology; 1978 Aug; 35(2):299-305. PubMed ID: 155646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
    Raje N; Hideshima T; Davies FE; Chauhan D; Treon SP; Young G; Tai YT; Avigan D; Gong J; Schlossman RL; Richardson P; Kufe DW; Anderson KC
    Br J Haematol; 2004 May; 125(3):343-52. PubMed ID: 15086415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
    Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
    Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Induction of efficient T-cell immunity against autologous leukemia cells by dendritic cells pulsed with the leukemia cell total RNA].
    Ge W; You SG; Wang YF; Li CH; Liu XF; He XP; Ma S; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):461-4. PubMed ID: 16383235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia.
    Roddie H; Klammer M; Thomas C; Thomson R; Atkinson A; Sproul A; Waterfall M; Samuel K; Yin J; Johnson P; Turner M
    Br J Haematol; 2006 Apr; 133(2):152-7. PubMed ID: 16611305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.
    Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Osterborg A; Mellstedt H
    Leukemia; 2003 May; 17(5):894-9. PubMed ID: 12750703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
    Bruserud O; Ulvestad E
    Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
    Zhong RK; Lane TA; Ball ED
    Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses.
    Koya RC; Kasahara N; Pullarkat V; Levine AM; Stripecke R
    Leukemia; 2002 Sep; 16(9):1645-54. PubMed ID: 12200676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
    Houtenbos I; Westers TM; Dijkhuis A; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Clin Cancer Res; 2007 Jan; 13(1):307-15. PubMed ID: 17170077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.